A review of recent research into myelodysplastic syndromes (MDS) shows a range of potential therapeutic targets. New research into the pathogenesis of myelodysplastic syndromes (MDS) may help aid the ...

Hypomethylating agents are standard in MDS treatment, with new drugs like Rytelo enhancing anemia management. Targeted therapies for IDH1/IDH2 mutations offer promising options, though challenges in ...

Myelodysplastic syndrome is an extremely heterogeneous disease, and there is no definitive cure, so these investigators wanted a better understanding of patients’ priorities regarding their care, ...

Myelodysplastic syndromes (MDS) are treated based on type and risk assessment, but traditional therapies may not work for everyone. Clinical trials offer a way to explore emerging treatments and ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. In terms of future MDS research, a lot of ...

FOSTER CITY, Calif., April 30, 2020 (GLOBE NEWSWIRE) -- Notable, which is redefining cancer treatment with its scientific technology platform to rapidly advance drug development, announced a ...

Smokers with myelodysplastic syndromes (MDS) or a precursor condition had elevated levels of genetic mutations linked to the disease, a new study shows. The study also found that heavier smokers ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. “It looks like, in the low-risk [myelodysplastic ...